RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/33519819http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/33519819http://www.w3.org/2000/01/rdf-schema#comment"Intestinal epithelial cells are adapted in mucosal hypoxia and hypoxia-inducible factors in these cells can fortify barrier integrity to support mucosal tissue healing. Here we investigated whether hypoxia-related pathways could be proposed as potential therapeutic targets for inflammatory bowel disease. We developed a novel hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, CG-598 which stabilized HIF-1α in the gut tissue. Treatment of CG-598 did not affect extra-intestinal organs or cause any significant adverse effects such as erythropoiesis. In the experimental murine colitis model, CG-598 ameliorated intestinal inflammation with reduction of inflammatory lesions and pro-inflammatory cytokines. CG-598 treatment fortified barrier function by increasing the expression of intestinal trefoil factor, CD73, E-cadherin and mucin. Also, IL-10 and IL-22 were induced from lamina propria CD4+ T-cells. The effectiveness of CG-598 was comparable to other immunosuppressive therapeutics such as TNF-blockers or JAK inhibitors. These results suggest that CG-598 could be a promising therapeutic candidate to treat inflammatory bowel disease."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.org/dc/terms/identifier"doi:10.3389/fimmu.2020.609689"xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Chang S.Y."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Chung J."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Ko H.J."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Lee A.R."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Cho J.M."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Kim S.R."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Kim Y.I."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Hong Y.R."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Kim Y.D."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Yi E.J."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Ha H.C."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/author"Cheon J.H."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/date"2020"xsd:gYear
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/name"Front Immunol"xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/pages"609689"xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/title"Local Stabilization of Hypoxia-Inducible Factor-1alpha Controls Intestinal Inflammation pii>viapi/i> Enhanced Gut Barrier Function and Immune Regulation."xsd:string
http://purl.uniprot.org/citations/33519819http://purl.uniprot.org/core/volume"11"xsd:string
http://purl.uniprot.org/citations/33519819http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/33519819
http://purl.uniprot.org/citations/33519819http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/33519819
http://purl.uniprot.org/uniprot/#_D0VY79-mappedCitation-33519819http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33519819
http://purl.uniprot.org/uniprot/#_B2R617-mappedCitation-33519819http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33519819
http://purl.uniprot.org/uniprot/#_A8MYV6-mappedCitation-33519819http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33519819